Chemomab Therapeutics annual operating expenses
2018
2019
2020
2021
2022
2023
2024
2025
Chemomab Therapeutics Operating Expenses Growth & History (CMMB)
Chemomab Therapeutics's operating expenses was $9.6M for fiscal 2025.
View full Chemomab Therapeutics company overviewChemomab Therapeutics annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $9.6M | −$5.2M | −35.09% |
| 2024 | 2024-12-31 | $14.7M | −$10.7M | −42.11% |
| 2023 | 2023-12-31 | $25.5M | −$3.1M | −10.77% |
| 2022 | 2022-12-31 | $28.5M | $16.2M | +130.72% |
| 2021 | 2021-12-31 | $12.4M | $6.4M | +107.08% |
| 2020 | 2020-12-31 | $6.0M | −$16.9M | −73.92% |
| 2019 | 2019-12-31 | $22.9M | $9.9M | +75.67% |
| 2018 | 2018-12-31 | $13.0M | — | — |
Chemomab Therapeutics quarterly operating expenses
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q2.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.2M | −$21,000 | −0.93% |
| Q1 2026 | 2026-03-31 | $1.9M | −$1.6M | −46.95% |
| Q4 2025 | 2025-12-31 | $2.0M | — | — |
| Q3 2025 | 2025-09-30 | $1.8M | — | — |
| Q2 2025 | 2025-06-30 | $2.3M | −$1.5M | −39.97% |
| Q1 2025 | 2025-03-31 | $3.5M | — | — |
| Q2 2024 | 2024-06-30 | $3.8M | −$4.4M | −54.02% |
| Q2 2023 | 2023-06-30 | $8.2M | $1.9M | +31.04% |
| Q1 2023 | 2023-03-31 | $9.0M | $3.7M | +70.09% |
| Q4 2022 | 2022-12-31 | $8.6M | $3.6M | +72.01% |
| Q3 2022 | 2022-09-30 | $8.3M | $5.4M | +187.69% |
| Q2 2022 | 2022-06-30 | $6.3M | $3.5M | +127.17% |
| Q1 2022 | 2022-03-31 | $5.3M | $3.6M | +213.13% |
| Q4 2021 | 2021-12-31 | $5.0M | $3.1M | +158.70% |
| Q3 2021 | 2021-09-30 | $2.9M | $1.7M | +136.00% |
| Q2 2021 | 2021-06-30 | $2.8M | $1.7M | +150.05% |
| Q1 2021 | 2021-03-31 | $1.7M | −$5,000 | −0.29% |
| Q4 2020 | 2020-12-31 | $1.9M | −$3.7M | −65.71% |
| Q3 2020 | 2020-09-30 | $1.2M | −$6.0M | −83.15% |
| Q2 2020 | 2020-06-30 | $1.1M | −$3.4M | −75.74% |
| Q1 2020 | 2020-03-31 | $1.7M | −$3.7M | −68.60% |
| Q4 2019 | 2019-12-31 | $5.7M | — | — |
| Q3 2019 | 2019-09-30 | $7.3M | — | — |
| Q2 2019 | 2019-06-30 | $4.5M | — | — |
| Q1 2019 | 2019-03-31 | $5.4M | — | — |
Chemomab Therapeutics operating expenses trends
Over the last five fiscal years, Chemomab Therapeutics's operating expenses increased from $6.0M to $9.6M, a change of $3.6M. The latest reported quarter, Q2 2026, shows $2.2M.
About the metric
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
Calculation and source
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Chemomab Therapeutics source filings ↗